4.1 Article

Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid

Journal

CLINICAL NEPHROLOGY
Volume 75, Issue 2, Pages 165-170

Publisher

DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CN106491

Keywords

Castleman's disease; thrombotic microangiopathy; rituximab; monoclonal anti-CD20 antibody

Ask authors/readers for more resources

Thrombotic microangiopathy (TMA) is a rare renal complication accompanied with Castleman's disease. We report the first case of TMA combined plasma cell type multicentric Castleman's disease (MCD) which was successfully treated with rituximab and corticosteroid. A previously healthy 60-year-old Korean man was admitted due to acute renal failure, thrombocytopenia, and multiple lymphadenopathies. The result of lymph node biopsy was plasma cell type Castleman's disease and TMA was revealed by kidney biopsy. After treatment with rituximab, prednisolone and temporary hemodialysis, complete remission was achieved. The combination of corticosteroid and rituximab was associated with improvement for this patient.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available